AbbVie : Form 8.1 - AbbVie Inc.

September 12, 2019 at 07:01 am

AbbVie Inc. - Form 8.1

NORTH CHICAGO, Ill., Sept. 12, 2019 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	6 August 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	1290	$65.06


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


Is a Supplemental Form 8 attached? (Note 9)	YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	6 September 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	1245	$67.2739


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities


(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	9 July 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	1281	$71.19


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Edward Liddy
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	30 June 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	22,669 (0.002%)
(2) Derivatives (other than options)	23,211 (0.002%)
(3) Options and agreements to purchase/sell	N/A
Total	45,880 (0.003%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Stock equivalent unit	Director fee credit to stock equivalent unit account	446	$72.72


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Edward J. Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	30 June 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	30,662 Common Shares (0.002%)
(2) Derivatives (other than options)	15,577 stock equivalent units (0.001%)
(3) Options and agreements to purchase/sell	N/A
Total	46,239 (0.003%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Stock equivalent unit	Director fee credit to stock equivalent unit account	467	$72.72


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	2 August 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	353,215 Common Shares (0.02%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	932,154 options (0.06%)
Total	1,285,369 (0.09%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Gift of common shares	15,333 common shares	$0


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	10 September 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	335,155 Common Shares (0.02%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	932,154 options (0.06%)
Total	1,267,309 (0.09%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Gift of common shares	15,010 common shares	$0


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities


(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	28 August 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	350,165 Common Shares (0.02%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	932,154 options (0.06%)
Total	1,282,319 (0.09%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Gift of common shares	3,050 common shares	$0


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Robert Alpern
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	30 June 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	26,107 (0.002%)
(2) Derivatives (other than options)	6,571 stock equivalent units (0.000%)
(3) Options and agreements to purchase/sell	N/A
Total	32,678 (0.002%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Stock equivalent unit	Director fee credit to stock equivalent unit account	94	$72.72


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Roxanne S. Austin
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	1 August 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	117,114 Common Shares (0.008%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	117,114 Common Shares (0.008%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase	25,000 common shares	$65.656


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Roxanne S. Austin
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	30 July 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	62,114 Common Shares (0.004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	62,114 Common Shares (0.004%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase	10,000 common shares	$66.35


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Roxanne S. Austin
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	31 July 2019


2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	92,114 Common Shares (0.006%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	92,114 Common Shares (0.006%)


(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total


3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase	30,000 common shares	$66.023


(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)


(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)


(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)


(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Is a Supplemental Form 8 attached? (Note 9) YES/NO?

Date of disclosure	11 September 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

CONTACT: Adelle Infante, 1-847-938-8745

Market Closed - London S.E. Other stock markets 11:30:00 2024-05-17 EDT			After market 13:18:11
164.5 ^USD	+0.62%		166.1	+0.97%

01:57pm	Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	MT
01:16pm	ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...

AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Pharmaceuticals

AbbVie : Form 8.1 - AbbVie Inc.

Latest news about AbbVie Inc.

Chart AbbVie Inc.

Company Profile

Income Statement Evolution

Ratings for AbbVie Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	07:57am	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	07:16am
Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	05-15
Medincell: share price falls after disappointing clinical study	05-15	CF
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders	05-13	MT
Medincell: share price rises on resumption of trading	05-09	CF
AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine	05-08	MT
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	05-08	MT
Health Canada Approves QULIPTA for the Preventive Treatment of Chronic Migraine in Adults	05-08	CI
Medincell: listing suspended pending a press release	05-08	CF
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	04-30	MT
Health Care Up on Growth Optimism -- Health Care Roundup	04-29	DJ
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	04-29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	04-29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	04-29	MT
Health Care Flat After Strong Earnings Week -- Health Care Roundup	04-26	DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET	04-26	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	04-26	DJ
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q	04-26	DJ
News Highlights : Top Company News of the Day - Friday at 3 PM ET	04-26	DJ
News Highlights : Top Company News of the Day - Friday at 1 PM ET	04-26	DJ
Top Midday Stories: Google Announces First-Ever Dividend; Oil Giants Down on Earnings Misses; Second Norfolk Southern Union Backs Activist Investor's Board Candidates	04-26	MT
News Highlights : Top Company News of the Day - Friday at 11 AM ET	04-26	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	04-26	MT
Well, it isn't as bad as feared...	04-26

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.14%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.56%	371B
MERCK & CO., INC.	+20.01%	331B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.54%	169B
PFIZER, INC.	-0.47%	164B